Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NormaLyte is a healthcare company specializing in medical-grade oral rehydration salts (ORS) designed specifically for patients with chronic conditions such as Postural Orthostatic Tachycardia Syndrome (POTS), Dysautonomia, and Ehlers-Danlos Syndrome (EDS). The company's products are formulated based on the World Health Organization's (WHO) standards for oral rehydration therapy, providing an efficient method for rapid electrolyte replenishment and volume expansion. NormaLyte distinguishes itself by offering specialized versions of its products, including a PURE line that is free from artificial sweeteners, flavors, and dyes to accommodate patients with high sensitivities. The company serves a niche but significant patient population that requires high-sodium intake to manage symptoms of orthostatic intolerance and chronic dehydration.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Normalyte.